Form 4: Akero Therapeutics Chief Development Officer Catriona Yale Executes Stock Option and Sells Shares
SEC Form 4 Filing
Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares of common stock on May 15, 2025, according to a Form 4 filing with the SEC.
Summary
- On May 15, 2025, Catriona Yale, the Chief Development Officer of Akero Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $21.10 per share.
- Yale then sold a total of 10,000 shares in multiple transactions at weighted-average prices of $38.199, $39.46 and $39.906.
- These sales resulted in Yale holding 95,034 shares of Akero Therapeutics common stock following the reported transactions.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports routine stock transactions by an officer.
Industry Context
This filing reflects routine insider transactions and provides insight into the trading activity of Akero Therapeutics' executives.
Key Dates
| Date | Description |
|---|---|
| 2024-05-24 | Date of adoption of Rule 10b5-1 trading plan. |
| 2025-05-15 | Date of stock option exercise and share sales. |
| 2025-05-19 | Date of signature on the Form 4 filing. |
| 2031-12-07 | Expiration date of the stock options. |
Keywords
Akero Therapeutics, AKRO, Catriona Yale, Chief Development Officer, Stock Options, SEC Form 4, Share Sales, Rule 10b5-1 Trading Plan, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.